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the introduction of PCV7, net costs averted are in the range of $5 million as a result 
of the implementation of PCV7 universal vaccination in Alberta. Over the time 
period, direct protection resulted in net cost savings of $2.6 million, and indirect 
benefits $2.4 million; the indirect benefits derived by elderly populations were more 
than one third of the total benefits derived across the population. ConClusions: 
This study is unique in that it uses validated surveillance data from Alberta to 
retrospectively assess the economic benefit of a public health policy, and describes 
the distribution of benefits across different segments of the population. From 2003 
to 2008, the cumulative cost impact of introducing PCV7 in the childhood immu-
nization program to the Alberta health system is approximately $5 million, half of 
which were a result of herd immunity.
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objeCtives: In pharmaceutical comparative effectiveness studies, patients fre-
quently discontinue drug treatments soon after initiation, potentially biasing esti-
mated costs attributed to treatments. A partitioned data structure may facilitate 
estimating costs in the presence of censoring. We compared health care utilization 
costs for two chronic obstructive pulmonary disease (COPD) treatments over a one-
year period using intent-to-treat (ITT) and as protocol (AP) approaches. Methods: 
Claims data from two managed care health plans from July 2004 through September 
2013 was used to compare annual health care costs for COPD patients treated with 
1) inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) or long-acting mus-
carinic antagonist (LAMA) (non-triple) therapy, or 2) concurrent ICS/LABA+LAMA 
(triple) therapy. Post-treatment costs were aggregated by 4-week periods. Costs were 
estimated for ITT and AP treatment groups, using actual and weighted cost methods. 
Patients were censored for health plan disenrollment (possible after 6 months post-
index). In the AP analysis, patients were additionally censored for discontinuation of 
treatment. Weights were the inverse probability of remaining uncensored. Results: 
Study subjects numbered 5,475; 484 triple, 4,991 non-triple. Few patients disenrolled 
(n= 139) by one-year post-index. ITT cost estimates were similar for actual and 
weighted cost methods. ITT actual mean total costs were significantly higher for 
triple therapy patients (P= 0.01): $20,013 (standard deviation [SD], $12,865) for triple, 
and $18,468 (SD, $11,619) for non-triple. Censoring was heavy in the AP analysis. 
Probability for remaining uncensored during the 13th four-week period was 28.5% 
for triple patients and 22% for non-triple patients. AP actual mean total costs were 
considerably lower than ITT costs: $12,586 (SD, $9,991) for triple therapy, $8,688 (SD, 
$7,896) for ICS/LABA or LAMA. AP weighted mean total costs were $19,133 for triple 
therapy and $16,814 for non-triple. ConClusions: The weighted method allowed 
censored individuals to contribute cost information. AP analysis costs were lower 
than ITT costs, highlighting the impact of therapy discontinuation on analyses.
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objeCtives: The prevalence of COPD is higher and increases every year in China. 
To estimate hospital inpatient costs, LOS and complication among patients with 
osteoporosis fractures in China. Methods: Data were extracted by the discharge 
diagnosis of COPD from the China Health Insurance Research Association claim 
database which includes a nationwide, cross-sectional sampling of inpatients’ visits 
in 2011. Several complications were chosen from reference to our objective compli-
cation, the inpatients’ visits with these complication were chosen by their diagnosis 
and drug used because the records were not integrity. The descriptive analysis of 
LOS, total medical costs and other parameters were calculated. Continuous vari-
ables were examined by student’s t test for we showed all results with mean value 
and standard deviation. The statistical software was SPSS. Results: The analysis 
included 8667 hospitalizations (Male: 62.71%, Age: 72.08±74 years). Overall LOS and 
costs were 16.17±25.70 days and 7949.59±11782.33 RMB. Sample of hospitalization 
with complication of heart failure was most ( 2503 ), followed by atrial fibrilla-
tion (AF), diabetes mellitus (DM), hypertension, osteoporosis, ischemic heart 
disease(IHD). While, patients with osteoporosis had the most hospitalization 
cost (17352.85±29584.08 RMB), followed by IHD (17140.08±25472.15 RMB), anxiety-
depression (16399.81±22671.54 RMB), DM (13709.27±22288.66 RMB) and hyper-
tension (13564.59±20725.80 RMB). For hospitalization cost, Men’s was more than 
women’s (8366.42 ±11034.93 vs. 7248.65 ±12913.71 RMB p< 0.05), employee’s was more 
than residents’ (9126.86±13026.41 vs. 4887.81 ±6753.29 RMB p< 0.001), inpatients’ 
(age over than 80 ) was the most (9697.75±12238.17, RMB p< 0.001), east’s was the 
most(10853.62±14751.43 RMB p< 0.001), prefecture-level city’s was the most(8039.55 
±14584.93 RMB 0.05< p< 0. 1). ConClusions: Heart failure was a common com-
plication among COPD patients, and osteoporosis increased the hospitalization 
cost for COPD patients which might be for the surgery. Hospitalization cost varied 
significantly among different patients and area, expect different level of city. The 
relationship between cost and complication should be studied further in future.
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objeCtives: To systematically assess the global economic burden associated with 
symptomatic COPD. Methods: A systematic search of Embase®, MEDLINE®, 
EconLit® and LILACS® was conducted for last 10 years along with search of con-
ference proceedings for last 3 years. Non-randomised trials and observational stud-
infection, MXN$123 million for pneumococcal diseases, MXN$199 million for HPV, 
and MXN$258 million for B. pertussis. Cost offsets in Year 1 after adoption of the 
immunization program totaled MXN$23 million for RSV infection, MXN$38 million 
for pneumococcal diseases, MXN$133 million for HPV, and MXN$206 million for 
B. pertussis. ConClusions: This model suggests that targeting RSV prophylaxis 
to high-risk populations can lead to substantial cost offsets, which are consistent 
with or improve on the budget impact of other preventive health programs for 
childhood diseases in Mexico.
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objeCtives: Arformoterol tartrate inhalation solution (arformoterol) is a long-act-
ing beta2-agonist indicated for long-term maintenance treatment of bronchocon-
striction in patients with chronic obstructive pulmonary disease (COPD). Nebulized 
albuterol (albuterol) is a short acting beta-agonist indicated as rescue medication 
for acute COPD exacerbations, but often patients receive it in place of maintenance 
treatment. This analysis estimated total medical, pharmacy and rehospitalization 
costs for nebulized arformoterol compared with albuterol nebulized solution for 
the management of COPD in hospitalized patients. Methods: An economic model 
was built comparing health care resource utilization and rehospitalization costs 
for arformoterol and albuterol from the hospital perspective. Pharmacy costs were 
calculated on a cost per hospital stay basis and were determined by the number 
of doses, frequency of administration, and hospital length of stay (LOS). Pharmacy 
costs were based on publically available wholesale acquisition costs. Medical costs 
included COPD exacerbation hospitalization costs, rehospitalization costs, and 
respiratory therapy costs. Cost of COPD-related inpatient hospitalizations were 
calculated as the cost per day times the mean LOS. Rehospitalization costs were 
calculated using rehospitalization rates at 30, 90, and 180 days. Respiratory ther-
apy costs were based on the number of daily sessions for administration and the 
hourly rate of respiratory therapy. Results: Mean LOS was 4.4 days for arformoterol 
vs. 5.2 days for albuterol. Arformoterol had lower rates of rehospitalization at 30, 
90 and 180 days post-discharge, respectively (8.7% vs. 11.9%, 15.4% vs. 26.8% and 
31.7% vs. 38.2%). Total medical and pharmacy costs per treated patient for arfor-
moterol were $6,953 vs. $8,456 for albuterol, resulting in a savings of $1,503 per 
patient. Arformoterol yielded net savings of $338, $1,025, and $847 over albuterol 
in rehospitalization cost per treated patient at 30, 90 and 180 days, respectively. 
ConCluSionS: Total costs of arformoterol were less than albuterol nebulized solu-
tion due to lower hospitalization and rehospitalization costs.
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objeCtives: To estimate the economic burden of lost productivity and health care 
resource use associated to tobacco in the Brazilian population among smoking 
and non-smoking/ex-smoking employees. Methods: A structured search was 
performed on MEDLINE database (via PubMed) using the MesH Database terms 
in accordance with the following terms ((“Costs and Cost Analysis” [Mesh]) AND 
(“Smoking” [Mesh]) AND (“ absenteeism” [Mesh]) AND (“presenteeism” [Mesh])), 
as well as the cost of absence days due to health events retrieved from national 
labor legislations; and average wage was retrieved from the Brazilian Institute for 
Geography and Statistics (IBGE) 2.013. Results: The disease costs related to tobacco 
are Cardiovascular disease (CVD) BRL 27,845.32; stroke BRL 20,591.24; Chronic 
obstructive pulmonary disease (COPD) BRL 21,328.59; pneumonia BRL 1,111.82; lung 
cancer BRL 67,225.83; other cancers BRL 85,524.46. When comparing the productivity 
and absence days, the smokers lose 62.1% more days than nonsmokers and 41.34% 
than ex-smokers, which corresponds to BRL 1,326.62 in terms of annual monetary 
average cost. Additionally, it was found that the life expectancy of male smokers 
corresponds to 75.30 years; for females, it already was 79.77 years. That means a 
loss of 5.03 and 4.5 years, respectively, when compared to the expected useful lives 
of the the nonsmoking population. ConClusions: Therefore, smoking employees 
can cost, on unproductive days, almost 3 times more than non-smokers and 2 times 
more than ex-smokers, besides the cost related to the treatment of stroke, COPD 
and CVD, and others.
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objeCtives: Acute respiratory tract infections caused by Streptococcus pneumoniae(SP) 
are a leading cause of morbidity and mortality in young children and the elderly. 
In 2002, Alberta introduced a pneumococcal universal immunization program for 
children, using Prevnar 7 (PCV7). In this study, we assess the economic impact of 
PCV7 on the Alberta health care system. Methods: Using active surveillance data 
from Alberta, we examine the net costs averted as a result of a decline in PCV7 
serotypes, accounting for the increase in costs due to serotype replacement. We 
also calculate the magnitude of herd immunity in terms of costs averted. Results: 
We find that following the introduction of PCV7 (2003-2008), the number of cases 
of invasive disease caused by vaccine serotypes declined significantly across all 
ages. Specifically, by 2008, there was considerable evidence of herd immunity as 
the incidence rates had declined nearly 100% across all ages. However, non-PCV7 
cases, on the other hand, increased. Assuming serotype replacement is a result of 
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Disease, 9th Revision, Clinical Modification (ICD-9-CM) code 493.xx. The first asthma 
diagnosis date was designated as the index date. Patients were required to have 12 
months continuous enrollment pre- and post-index date. Comorbid conditions were 
examined for the baseline period. Study outcomes including treatment patterns 
within 60 days after the index date, health care utilization and costs in the Medicare 
research identifiable file during the follow-up period were measured. Results: A 
total of 63,012 patients were identified for study, of which the majority was White 
(84.7%), male (68.2%) and resided in the Southern U.S. region (38.3%). The mean 
age of patients was 76 years. The Charlson Comorbidity Index score was 2.39, and 
common comorbidities included chronic obstructive pulmonary disease (42.9%), 
diabetes (33.2%) and tumor (30.2%). Patients were more often prescribed albuterol 
sulfate (19.1%), hydrocodone bitartrate/acetaminophen (14.4%) and furosemide 
(13.1%). Health care utilizations included Medicare carrier use (99.0%), Durable 
Medical Equipment (DME, 51.7%), Home Health Agency (HHA, 22.3%), outpatient 
visits (81.6%) and inpatient (40.8%), Skilled Nursing Facility (SNF, 12.6%) and hos-
pice admissions (5.0%) and prescription drug (part D event) claims (57.3%). Patient 
expenditures were calculated at $5,431 for Carrier, $726 for DME, $1,401 for HHA, 
$15,211 for outpatient, $9,162 for inpatient, $2,354 for SNF, $464 for hospice, $2,192 
for pharmacy and $36,941 for total costs. ConClusions: U.S. Medicare patients 
diagnosed with asthma were more often prescribed albuterol sulfate, experienced 
a high percentage of Medicare carrier service use and outpatient visits, as well as 
frequent comorbidities, which translated into high total health care expenses as 
evidenced by this study.
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objeCtives: Global clinical guidelines recommend fixed-dose combinations 
(FDCs) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABA), 
delivered via an inhaler, as a treatment for moderate to severe persistent asthma 
and chronic obstructive pulmonary disease (COPD).  Poor inhalation technique—
measured as the occurrence of critical inhaler errors—is common with existing 
inhalers, and may contribute to the economic burden of disease management by 
increasing health care resource use. We have developed an economic model to 
evaluate the clinical and economic burden of asthma and COPD in the UK, and 
assess the impact of poor inhalation technique with ICS + LABA FDCs on costs 
and resource use. Methods: The eligible adult patient population was based on 
current confirmed asthma and COPD diagnosis rates in the UK, with the propor-
tion of patients receiving FDCs based on available market research data.  Costs 
of inhalers, scheduled care and unscheduled health care events were taken from 
publicly available sources in the UK.  Frequency of poor inhalation technique—
measured through the occurrence of critical inhaler errors—and the associated 
increased risk of unscheduled health care events were taken from a large (n = 1,664) 
cross-sectional, observational study in Italy. Results: The model estimated that 
1.3 million adults with persistent asthma and COPD receive an ICS + LABA FDC 
in the UK, annually; of which, 366,000 demonstrate poor inhalation technique. 
Total direct costs were estimated to be £875 million, with costs of unscheduled 
health care events accounting for £137 million.  Poor inhalation technique with 
ICS + LABA FDCs was estimated to be responsible for 11.8% of unscheduled health 
care costs, equating to £16.2 million annually. ConClusions: The clinical and 
economic burden associated with poor inhalation technique in asthma and COPD 
is considerable in the UK.  Novel inhalers, which improve inhalation technique, 
may offer clinical and economic benefits in the management of asthma and COPD.
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WithdRaWn
ies involving symptomatic patients defined as modified Medical Research Council 
(mMRC) score ≥ 2 or COPD assessment test (CAT) score ≥ 10 or presenting common 
symptoms of COPD were included. Studies focussed on cost of illness and resource 
use in adult symptomatic COPD patients were included. Studies meeting the eli-
gibility criteria were appraised using Drummond checklist. Results: Database 
searches yielded 4491 references which resulted in 74 relevant studies after two 
levels of screening. All the included studies were of adequate reporting quality 
with study objective and competing alternatives being defined clearly. The annual 
direct per patient costs of COPD ranged from US$522 in France to US$4119 in the 
United States. Physician consultations were the most frequently utilised resource, 
followed by ER visits and hospitalisations. The composition of direct costs differed 
between countries, with more than 50% of the direct costs resulting due to inpatient 
admissions in Canada, Italy, Spain, the UK, and the United States and almost 50% 
due to regular prescribed medicines in The Netherlands. The mean annual societal 
costs ranged from US$1023 in The Netherlands to US$5646 in the United States. The 
annual societal costs per patient were higher in patients with severe COPD, higher 
levels of dyspnoea and symptoms, frequent exacerbations, comorbid conditions, low 
educational status and former smokers. Economic burden of lost productivity was 
the highest in the US and the lowest in Italy. Lost productivity accounted for 67% of 
the total cost of COPD in France. ConClusions: The management of symptomatic 
COPD is associated with a substantial economic burden, especially in the developed 
nations of Europe and North America.
PRS27
outPatient diReCt CoSt of CoPd in a thiRd level hoSPital: Patient 
PeRSPeCtive
Martinez-Briseño D., Fernandez_Plata M.R., Ramirez-Venegas A., Sansores-Martínez R., 
Jimenez-Cano D., Garcia-Sancho C.
National Institute of Respiratory Diseases “Ismael Cosío Villegas”, Mexico City, Mexico
objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a main worldwide 
cause of morbidity and mortality. COPD elderly patients spend a large amount of 
money; elderly population is rapidly increasing due to population aging. COPD preva-
lence in 40 years or older people is 7.8% in Mexico City. However, there is no infor-
mation about out-out-pocket expenses of COPD patients in Mexico. Te objective is 
to estimate direct costs of COPD from patient perspective in a third level hospital 
in Mexico. Methods: A pool was developed from august to november of 2013 in a 
third level hospital. We included outpatients and inpatients that had been already 
diagnosed and newly diagnosed with COPD. The diagnosis was carried out by a pul-
monologist according to GOLD criteria. We collected information about direct and 
indirect costs of the patients and the hospital. We estimate median (p25, p75) annual 
cost of medical consultation, clinical test, travel, gasoline and food from outpatients 
and stratifying by severity. All cost were transformed in US Dollars of 2103. Results: 
We interviewed 242 outpatients. According GOLD criteria the patients were classified 
as: mild (n= 18), moderate (n= 105), severe (n= 80) and very severe (n= 39). Median of age 
was 71.7 years, 141 (58.3%) were men and 133 (54.9%) had social security. Annual total 
costs for mild, moderate, severe and very severe were $64.5, $99.9, $130.7 and $138.4, 
respectively. Median costs from mild to very severe were: medical consultation ($23.1, 
$27.7); Clinical test ($11.6, $48.4); travel ($2.2, $33.8); gasoline ($6.9, $13.9) and food ($0, 
18.4). ConClusions: According to total cost, severity is positively correlated with 
the amount of out-of-pocket expenses. The main sources of expenses were medical 
consultations and clinical test.
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objeCtives: Nowadays, health care costs of asthma are under pressure in all coun-
tries due to high prevalence, incidence and the chronic nature of disease. Therefore, 
conducting cost analysis of economic burden of asthma is necessary, especially in 
Vietnam. This is also the aim of this study. Methods: The average cost of asthma 
has been evaluated using pharmacoeconomic method “cost of illness” by following 
formula: COI = DC + IC in which: COI - cost of illness, DC- direct cost, IC- indirect cost 
A tree-decision model has been developed to evaluate the cost of asthma by differ-
ent classification of the severity of asthma. Based on the perspective of insurance 
companies only direct medical costs were evaluated in this study. List of medical ser-
vices and drugs were derived from Guidelines for the diagnosis and management of 
asthma in Vietnam. The price of drugs and medical services have been averaged from 
the price-list of some major hospitals in Vietnam. The cost of disease for the whole 
society of Vietnam has been evaluated based on the cost of disease and the number 
of patients in Vietnam in 2013. Results: The average direct medical cost of asthma 
has increased by the increasing of asthma severity with 3,410,278; 6,548,156; 8,829,234; 
10,746,280 VND in the intermittent, mild, moderate and severe rate of disease severity. 
In the structure of direct cost, with the increasing of asthma severity the percentage of 
costs for drugs increases and the one for medical services reduces. The average direct 
cost of asthma for the whole society of Vietnam resulted in nearly 16,585 billion VND 
per year. ConClusions: The cost of asthma management increases following the 
increasing of disease severity. The high economic burden of asthma (16,585 billion 
VND) should be considered to conduct the relevant health care policies.
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objeCtives: To assess the economic burden and health care utilizations of asthma 
patients in the U.S. Medicare population. Methods: A retrospective analysis was 
conducted using national Medicare data (01JAN2008-31DEC2010). All Medicare bene-
ficiaries diagnosed with asthma were identified using International Classification of 
